Recent Updates
Recently added Catalysts
ANRO Negative Sentiment Score: 25/100

ALTO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Contact the Firm

Key Takeaway: A class action lawsuit has been filed against Alto Neuroscience, Inc. (ANRO) for allegedly misleading investors about the efficacy of its treatment, ALTO-100, for major depressive disorder. The lawsuit claims that the company failed to disclose key information that overstated the treatment’s clinical and commercial prospects. Following the announcement of disappointing Phase 2b trial results, Alto's stock dropped significantly, highlighting investor losses during the class period. Affected investors are encouraged to participate in the lawsuit by contacting Bragar Eagel & Squire, P.C.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed, indicating potential legal troubles for Alto Neuroscience.
  • Alto's ALTO-100 was reportedly less effective in treating major depressive disorder than claimed, impacting investor confidence.
  • The company's financial prospects seem overstated based on public disclosures, leading to a significant loss in stock price.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Alto between February 2, 2024 and October 22, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE:ANRO) in the United States District Court Northern District Of California on behalf of all persons and entities who purchased or otherwise acquired Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”). Investors have until September 19, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
According to the complaint, the Offering Documents in support of the IPO were negligently prepared. Additionally, during the class period, defendants failed to disclose that: (i) ALTO-100 was less effective in treating MDD than defendants had led investors to believe; (ii) accordingly, ALTO-100’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, Alto’s business and/or financial prospects were overstated.
On October 22, 2024, Alto issued a press release announcing topline results from the Phase 2b trial evaluating ALTO-100 as a treatment for MDD. That press release stated, in relevant part, that “ALTO-100 in patients with [MDD] did not meet its primary endpoint, assessed by a change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS), compared to placebo.” On this news, Alto’s stock price fell $10.17 per share, or 69.99%, to close at $4.36 per share on October 23, 2024.
If you purchased or otherwise acquired Alto shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

How can I contact the law firm for Alto investor claims?

You can reach out to Brandon Walker or Marion Passmore at (212) 355-4648.

What is the deadline to apply as lead plaintiff in the lawsuit?

The deadline to apply as lead plaintiff is September 19, 2025.

Why is Alto being sued in the class action lawsuit?

Alto is sued for allegedly misleading investors about ALTO-100's effectiveness.

What happened to Alto's stock price after the trial results?

Alto's stock price dropped 69.99% to $4.36 per share following the news.

Is there a cost to participate in the lawsuit against Alto?

There is no cost or obligation to you for participating in the lawsuit.

Last updated: Sep 3, 2025